PLUS1
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Galmed Pharmaceuticals Ltd | GLMD | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 6.20 | 0.00 | 0.00 | 0.00 | 6.20 | 04:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 3.50 | 14.49 | 10.99 | 75.85% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
Galmed Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 130.97M | 21.12M | $ -9.86M | -0.57 | - | 21.12M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Galmed Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/06/2019 | 07:11 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 11/06/2019 | 07:00 | PR Newswire (US) | Galmed Pharmaceuticals Provides Business Update and Reports.. |
| 10/31/2019 | 09:04 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 10/31/2019 | 08:30 | PR Newswire (US) | Galmed Pharmaceuticals to Present New Data on Aramchol.. |
| 10/30/2019 | 08:30 | PR Newswire (US) | Galmed Pharmaceuticals to Report Third Quarter 2019.. |
| 9/26/2019 | 08:12 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 9/26/2019 | 08:00 | PR Newswire (US) | Galmed Pharmaceuticals Initiated ARMOR, a Phase 3/4.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLMD Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.95 | 7.15 | 5.80 | 6.38 | 188,704 | -0.75 | -10.79% |
| 1 Month | 4.46 | 7.38 | 4.30 | 6.09 | 173,650 | 1.74 | 39.01% |
| 3 Months | 4.92 | 7.38 | 3.4179 | 5.13 | 110,126 | 1.28 | 26.02% |
| 6 Months | 5.72 | 7.70 | 3.4179 | 5.31 | 87,729 | 0.48 | 8.39% |
| 1 Year | 8.22 | 9.74 | 3.4179 | 6.71 | 98,871 | -2.02 | -24.57% |
| 3 Years | 3.36 | 27.06 | 3.04 | 11.50 | 139,460 | 2.84 | 84.52% |
| 5 Years | 4.90 | 27.06 | 2.78 | 10.66 | 101,841 | 1.30 | 26.53% |
Galmed Pharmaceuticals Description
| Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. |
